Please ensure Javascript is enabled for purposes of website accessibility

Cresco Labs Had a Good Start to 2020. Can It Keep It Up?

By Sushree Mohanty – Jun 11, 2020 at 5:30AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This U.S. cannabis company showed astounding revenue growth with expansion plans amid the COVID-19 pandemic.

U.S. cannabis companies are certainly catching attention this year. No doubt, they were overlooked while eyes were on the bigger Canadian cannabis players, like Aurora Cannabis (ACB -1.64%) and Canopy Growth (CGC 4.41%). But while the bigger names failed to impress with their downfall the past few quarters, Illinois-based Cresco Labs (CRLBF -9.30%) is emerging as a good cannabis pick for 2020.

Staggering revenue growth

Cresco Labs' incredible revenue growth of 215% in the first quarter is a proof of the rising cannabis demand in the U.S. It grew revenue to $66.4 million compared to $21.0 million in the year-ago period.

Sequentially, revenue also rose from $41.4 million in the fourth quarter of fiscal 2019. The company has been reporting revenue growth from the last two quarters while Canadian peers were battling the headwinds. Canada's slow roll-out of legal stores is responsible for pulling down revenue growth for most. Meanwhile, more U.S. states have been working to legalize cannabis.

Among them, Illinois, which legalized recreational cannabis on Jan. 1, has been seeing a drastic rise in sales. It recorded $37.3 million in legal adult weed sales in April, the first month of complete lockdown due to the coronavirus pandemic.

Cannabidiol oil bottle and cannabis leaves

Image source: Getty Images.

Management sees tremendous potential in the Illinois market, which they think could grow to a $1 billion industry in its first year. Regulatory holdups in Massachusetts and Nevada constricted Cresco's growth in Q1. However, its diversified footprints allowed it to focus and drive growth from other markets where demand was surging. Cresco Labs' revenue growth in Q1 is attributed to three key U.S. markets: Pennsylvania, Illinois, and California.

What about profitability?

Not only were its revenue numbers good, but it has been profitable as well. In the first quarter, Cresco Labs reported adjusted earnings before interest, tax, depreciation, and amortization (EBITDA) of $3.2 million, compared to a profit of $2.8 million in the fourth quarter of fiscal 2019 and a loss of $138,000 in the first quarter last year. It's important to note these EBITDA figures are 'net of impact of biological assets,' an important distinction for cannabis stocks. Management expects increased profitability in the upcoming quarter from their growing business in the strong markets.

Besides Cresco, Illinois-based Green Thumb Industries (GTBIF -6.20%) and Massachusetts-based Curaleaf Holdings (CURLF -7.14%) also saw a revenue increase of 268% and 174%, respectively, year over year in their first quarter. In May, shares of Cresco Labs, Green Thumb, and Curaleaf were up 35%, 50%, and 37% respectively, compared with the SPDR S&P 500 ETF's (SPY -1.68%) gain of 7.6%. 


Image Source: YCharts

Continued expansion amid the pandemic

Smaller U.S. cannabis companies are on the verge of bankruptcy owing to no access to capital, as marijuana is federally illegal and faces limitations on receiving capital from banks. Meanwhile, Cresco Labs announced an expansion plan in key U.S. markets -- which gives me confidence in its ability to not only stay afloat amid the pandemic but also thrive post-crisis. 

Before its Q1 earnings, Cresco announced it will buy four additional Ohio dispensaries through a partnership with Verdant Creation -- making the total five dispensaries in the state. The company saw Ohio's average weekly cannabis sales grow 33% from February to April, which convinced them to expand in the state. It currently has a stellar combined capacity of 215,000 square feet of cultivation space that will allow it to increase its supply to meet rising demand.

In May, it also opened its sixth store in Illinois and its first adult-use dispensary in downtown Chicago.

Hold on to this stock

Cresco being a vertically integrated cannabis company is a plus point. Having control over the supply chain can help a company grow at its desired pace -- which most cannabis companies are struggling with amid the pandemic. 

Another priority to survive a crisis is to have a strong balance sheet. Cresco ended the quarter with $68.6 million in cash and cash equivalents.

Given the pandemic and how other businesses are struggling to survive, Cresco Labs had a good start to fiscal 2020. Luckily, if marijuana sales continue at the same pace, we could see higher revenue growth and increased profitability from Cresco this year.

The marijuana sector -- mainly the U.S. cannabis companies -- seems to be in a good place now with a chance to recover and grow. That said, looking for long-term growth from marijuana stocks will need a bit of patience and a stomach for risk. 

Sushree Mohanty has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Cresco Labs Inc. and Green Thumb Industries. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Cresco Labs Inc. Stock Quote
Cresco Labs Inc.
$2.73 (-9.30%) $0.28
SPDR S&P 500 ETF Trust Stock Quote
SPDR S&P 500 ETF Trust
$367.95 (-1.68%) $-6.27
Aurora Cannabis Stock Quote
Aurora Cannabis
$1.20 (-1.64%) $0.02
Canopy Growth Stock Quote
Canopy Growth
$2.84 (4.41%) $0.12
Green Thumb Industries Stock Quote
Green Thumb Industries
$9.99 (-6.20%) $0.66
Curaleaf Holdings, Inc. Stock Quote
Curaleaf Holdings, Inc.
$5.20 (-7.14%) $0.40

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.